Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.
This report contains market size and forecasts of Idiopathic Hypersomnia Treatment in Global, including the following market information:
Global Idiopathic Hypersomnia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Idiopathic Hypersomnia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Stimulant Medications Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Idiopathic Hypersomnia Treatment include Takeda Pharmaceutical, Teva Pharmaceutical Industries, Jazz Pharmaceuticals, BIOPROJET, Avadel Pharmaceuticals, GlaxoSmithKline, Pfizer, Theranexus and Fisher and Paykel Healthcare, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Idiopathic Hypersomnia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Idiopathic Hypersomnia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Idiopathic Hypersomnia Treatment Market Segment Percentages, by Type, 2021 (%)
Stimulant Medications
Non-Stimulant Wake-Promoting Medications
Sodium Oxybate
Global Idiopathic Hypersomnia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Idiopathic Hypersomnia Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Idiopathic Hypersomnia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Idiopathic Hypersomnia Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Idiopathic Hypersomnia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Idiopathic Hypersomnia Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Jazz Pharmaceuticals
BIOPROJET
Avadel Pharmaceuticals
GlaxoSmithKline
Pfizer
Theranexus
Fisher and Paykel Healthcare
Drive DeVilbiss Healthcare
Merck